IVOSIDENIB AND BEVACIZUMAB IN HEAVILY PRETREATED PATIENTS WITH IDH1 MUTANT GLIOMAS

被引：0
|
作者：
Patel, Mallika P. [1 ]
Ziv, Michal Nisnboym [1 ]
Minor, Maria [1 ]
Johnson, Margaret O. [1 ]
Batich, Kristen [1 ]
Low, Justin [1 ]
Shoaf, Madison L. [1 ]
Khasraw, Mustafa [1 ]
Friedman, Henry S. [1 ]
Ashley, David M. [1 ]
Desjardins, Annick [1 ]
Peters, Katherine B. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0670
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
INNV-07
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Increased Frequency of Presenting with Seizures in Patients with Isocitrate Dehydrogenase 1 (IDH1) Mutant Gliomas
    Chou, Arthur Po-Fei
    Ching, Harry
    Chang, Stephen
    Carrillo, Jose
    Lalezari, Shadi
    Spasic, Marko
    Choy, Winward
    Kim, Andrew
    Selfridge, Julia
    Quan, Jennifer
    Philippou, Yiannis
    Dye, Justin
    Soto, Horacio
    Nagasawa, Daniel
    Mathern, Gary
    Green, Richard
    Yang, Issac
    Prins, Robert
    Lai, Albert
    Liau, Linda
    JOURNAL OF NEUROSURGERY, 2012, 117 (02) : A440 - A440
  • [22] Metabolism, Gliomas, and IDH1
    Smeitink, Jan
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (12): : 1144 - 1145
  • [23] Ivosidenib for Patients with Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
    Petrone, Giulia
    Stein, Eytan M.
    Bolton, Kelly L.
    BLOOD, 2023, 142
  • [24] IDH1 Mutations in Gliomas
    Ohgaki, Hiroko
    Watanabe, Takuya
    Nobusawa, Sumihito
    Kleihues, Paul
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2009, 68 (05): : 559 - 559
  • [25] Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
    Borodovsky, Alexandra
    Seltzer, Meghan J.
    Riggins, Gregory J.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (01) : 83 - 89
  • [26] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Bin Fan
    Ingo K. Mellinghoff
    Patrick Y. Wen
    Maeve A. Lowery
    Lipika Goyal
    William D. Tap
    Shuchi S. Pandya
    Erika Manyak
    Liewen Jiang
    Guowen Liu
    Tara Nimkar
    Camelia Gliser
    Molly Prahl Judge
    Sam Agresta
    Hua Yang
    David Dai
    Investigational New Drugs, 2020, 38 : 433 - 444
  • [27] Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
    Tap, William D.
    Villalobos, Victor M.
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Mir, Olivier
    Beeram, Murali
    Wagner, Andrew J.
    Jiang, Liewen
    Wu, Bin
    Choe, Sung
    Yen, Katharine
    Gliser, Camelia
    Fan, Bin
    Agresta, Sam
    Pandya, Shuchi S.
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1693 - +
  • [28] IDH1 mutations in gliomas
    Ohgaki, H.
    Watanabe, T.
    Nobusawa, S.
    Kleihues, P.
    VIRCHOWS ARCHIV, 2009, 455 : 21 - 21
  • [29] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Lowery, Maeve A.
    Goyal, Lipika
    Tap, William D.
    Pandya, Shuchi S.
    Manyak, Erika
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Gliser, Camelia
    Judge, Molly Prahl
    Agresta, Sam
    Yang, Hua
    Dai, David
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 433 - 444
  • [30] Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML
    Stone, Richard M.
    Choe, Sung
    Zhang, Vickie
    Marteyn, Benoit
    Penard-Lacronique, Virginie
    Wang, Hongfang
    DiNardo, Courtney D.
    Stein, Eytan M.
    Fathi, Amir T.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Attar, Eyal C.
    Wu, Bin
    de Botton, Stephane
    BLOOD, 2017, 130
12345